Eye drug showdown: which works better for diabetic vision loss?
NCT ID NCT06850571
First seen Nov 01, 2025 · Last updated Jun 04, 2026 · Updated 27 times
Summary
This study compares two eye injections, aflibercept and bevacizumab, in 102 Iraqi adults with diabetic maculopathy (a diabetes-related eye disease that causes vision loss). The goal is to see which drug better improves vision and reduces eye swelling, and which is more cost-effective. Participants will receive three monthly injections, and their vision, eye thickness, and side effects will be tracked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Baghdad Medical City Complex
RECRUITINGBaghdad, 10001, Iraq
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.